drugset / Trial / NCT02512029

18F-AV-1451 PET Imaging in TBI

NCT02512029

Phase 1 Withdrawn Avid Radiopharmaceuticals
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This study will evaluate imaging characteristics of 18F-AV-1451 in subjects with subacute traumatic brain injury.

Timeline

Start
2015-10
Primary completion
2017-04
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir F18 Diagnostic / imaging agent 370 mbq Intravenous